|Articles|March 6, 2014

INC Research, LLC Acquired MEK Consulting

Acquisition provides customers improved access to Middle East and North Africa region as well as Southern Europe

INC Research, LLC has acquired MEK Consulting, a clinical monitoring-focused CRO based in Lebanon with operations in Greece, Turkey and the Middle East and North Africa (MENA) region. Through the acquisition, INC would have access to the over 200 million potential patients in the region.

Read the full release here.

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Trending on Applied Clinical Trials Online

Why Clinical Trial Modernization Fails Without Point-of-Care Data: Q&A with Richard Graham, PhD, TruTechnologies

Real-Time Trials Need More Than AI: Why Operational Trial Infrastructure Matters

ACT Brief: Lean Development Through Fractional Teams and Partners, FDA Expedited IND Pilot for Phase I Acceleration, and Tudriqev Accelerated Approval for Anti-PD-1-Refractory Melanoma

INC Research, LLC Acquired MEK Consulting

Related Content

Breaking the Efficacy Ceiling in IBD and Beyond

ACT Brief: Substance Versus Branding in Biotech Support, Site-Level Execution Gaps and Point-of-Care Data, and KCNT1-Targeted Pediatric Epilepsy Program

Why Clinical Trial Modernization Fails Without Point-of-Care Data: Q&A with Richard Graham, PhD, TruTechnologies

How to Tell Substance from Branding in Biotech's Support Ecosystem

ACT Brief: Lean Development Through Fractional Teams and Partners, FDA Expedited IND Pilot for Phase I Acceleration, and Tudriqev Accelerated Approval for Anti-PD-1-Refractory Melanoma

Trending on Applied Clinical Trials Online

Why Clinical Trial Modernization Fails Without Point-of-Care Data: Q&A with Richard Graham, PhD, TruTechnologies

Real-Time Trials Need More Than AI: Why Operational Trial Infrastructure Matters

ACT Brief: Lean Development Through Fractional Teams and Partners, FDA Expedited IND Pilot for Phase I Acceleration, and Tudriqev Accelerated Approval for Anti-PD-1-Refractory Melanoma

FDA Makes Case for Overhauling Early Clinical Development to Reclaim US Leadership

ACT Brief: Commercial Strategy Shaping Early Clinical Development, Real-Time Trials Require Operational Infrastructure, and AI Site Engagement Gap